Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven®)

被引：72

作者：

Tanaka, KA

Waly, AA

Cooper, WA

Levy, JH

机构：

[1] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA

[2] Emory Univ, Sch Med, Dept Cardiothorac Surg, Atlanta, GA 30322 USA

[3] Emory Healthcare, Div Cardiothorac Anesthesiol & Crit Care, Atlanta, GA USA

来源：

ANESTHESIOLOGY | 2003年 / 98卷 / 06期

关键词：

D O I：

10.1097/00000542-200306000-00034

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

[No abstract available]

引用

页码：1513 / 1515

页数：3

共 16 条

[1] Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery [J].

Al Douri, M ;

Shafi, T ;

Al Khudairi, D ;

Al Bokhari, E ;

Black, L ;

Akinwale, N ;

Musa, MO ;

Al Homaidhi, A ;

Al Fagih, M ;

Andreasen, RB .

BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 :S121-S127

[2]

d'Oiron R, 2000, THROMB HAEMOSTASIS, V83, P644

[3] Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery [J].

Dietrich, W ;

Spannagl, M .

ANESTHESIA AND ANALGESIA, 2002, 94 (05) :1369-1370

[4] The effect of the administration of recombinant activated factor VII (NovoSeven®) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy:: the PROSE study [J].

Friederich, PW ;

Geerdink, MGF ;

Spataro, M ;

Messelink, EJ ;

Henny, CP ;

Büller, HR ;

Levi, M .

BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 :S129-S132

[5] NovoSeven® as a universal haemostatic agent [J].

Hedner, U .

BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 :S107-S111

[6] An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII [J].

Hendriks, HGD ;

van der Maaten, JMAA ;

de Wolf, J ;

Waterbolk, TW ;

Slooff, MJH ;

van der Meer, J .

ANESTHESIA AND ANALGESIA, 2001, 93 (02) :287-289

[7] Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation - A pilot study [J].

Hendriks, HGD ;

Meijer, K ;

de Wolf, JTM ;

Klompmaker, IJ ;

Porte, RJ ;

de Kam, PJ ;

Hagenaars, AJM ;

Melsen, T ;

Slooff, MJH ;

van der Meer, J .

TRANSPLANTATION, 2001, 71 (03) :402-405

[8] RECOMBINANT FACTOR-VIIA FOR INTRACRANIAL HEMORRHAGE IN A JEHOVAH-WITNESS WITH SEVERE HEMOPHILIA-A AND FACTOR-VIII INHIBITORS [J].

MAJUMDAR, G ;

SAVIDGE, GF .

BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (06) :1031-1033

[9] MANAGEMENT OF THE SEVERELY ANEMIC PATIENT WHO REFUSES TRANSFUSION - LESSONS LEARNED DURING THE CARE OF A JEHOVAH WITNESS [J].

MANN, MC ;

VOTTO, J ;

KAMBE, J ;

MCNAMEE, MJ .

ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) :1042-1048

[10] Recombinant activated factor VII for adjunctive hemorrhage control in trauma [J].

Martinowitz, U ;

Kenet, G ;

Segal, E ;

Luboshitz, J ;

Lubetsky, A ;

Ingerslev, J ;

Lynn, M .

JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2001, 51 (03) :431-438

← 1 2 →